drugset / Trial / NCT04523883
Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)
Phase 2
Unknown
316 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Central South University · collabEye & ENT Hospital of Fudan University · collabFirst Affiliated Hospital of Fujian Medical University · collabFudan University · collabGuizhou Provincial People's Hospital · collabTianjin Medical University Cancer Institute and Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To investigate weather concurrent JS001 with postoperative radiotherapy would have survival benefit in intermediate/high Risk HNSCC Patients who cannot take cisplatin
Timeline
- Start
- 2020-08-10
- Primary completion
- 2022-08-09
- Completion
- 2024-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |